Drug intelligence / Profile preview

MY007

Development stage: Preclinical
Lead developer: Wuhan Createrna Science and Technology

Overview

**MY007** is an investigational Chinese Medicine Class 1.1 product developed by Monyan Pharmaceutical. The sponsor's R&D pipeline lists MY007 as having obtained clinical approval in 2025. Its molecular composition, dosage form, route of administration, specific oncology-supportive-care indication, and molecular mechanism have not been publicly disclosed. ([en.monyan.cn](https://en.monyan.cn/index.php/lists/65.html))

Beyond the preview

Go deeper on MY007.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MY007.